Emergent BioSolutions Inc. (EBS)
NYSE · Healthcare
Emergent BioSolutions Inc. Long Term Debt 2009–2025
Emergent BioSolutions Inc. annual long term debt history from 2010 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- Emergent BioSolutions Inc. long term debt as of December 31, 2025: 589.7M, a 15.76% decrease year-over-year.
- Emergent BioSolutions Inc. long term debt for 2025 were 589.7M, a 15.76% decrease from 2024.
- Emergent BioSolutions Inc. long term debt for 2024 were 700.0M, a 19.39% decrease from 2023.
- Emergent BioSolutions Inc. long term debt for 2023 were 868.4M, a 38.58% decrease from 2022.
- Emergent BioSolutions Inc. long term debt for 2022 were 1.41B.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Emergent BioSolutions Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $590 |
| 2024 | $700 |
| 2023 | $868 |
| 2022 | $1,414 |
| 2021 | $850 |
| 2020 | $886 |
| 2019 | $823 |
| 2018 | $809 |
| 2017 | $14 |
| 2016 | $248 |
| 2015 | $247 |
| 2014 | $251 |
| 2013 | $62 |
| 2012 | $63 |
| 2011 | $59 |
Emergent BioSolutions Inc. Long Term Debt — FAQ
Emergent BioSolutions Inc. (EBS) long term debt over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see EBS's long term debt history?
The chart and table above show Emergent BioSolutions Inc.'s long term debt by year and by quarter, including the growth rate.